Publication: Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset graves' disease
Issued Date
2008-06-01
Resource Type
ISSN
0334018X
Other identifier(s)
2-s2.0-48449105008
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Pediatric Endocrinology and Metabolism. Vol.21, No.6 (2008), 539-543
Suggested Citation
Ouyporn Panamonta, Vasant Sumethkul, Piyanuth Radinahmed, Malinee Laopaiboon, Wichitr Kirdpon Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset graves' disease. Journal of Pediatric Endocrinology and Metabolism. Vol.21, No.6 (2008), 539-543. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/18911
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset graves' disease
Other Contributor(s)
Abstract
Propylthiouracil (PTU) can induce anti-myeloperoxidase (MPO-ANCA) positive vasculitis. We performed a cross-sectional study to estimate the prevalence of MPO-ANCA in patients with childhood onset Graves' disease (GD) receiving PTU and to assess the relationship between ANCA and clinical manifestations of vasculitis. We studied 60 patients (59 girls and one boy) between 7.3 and 25.0 years of age (mean ± SD, 14.71 ± 4.49). GD, diagnosed at the age of 3.0 to 14.5 years (11.3 ± 2.48), was designated as: newly diagnosed, on PTU therapy, and after PTU discontinuation in 4, 50 and 6 patients, respectively. Manifestations of vasculitis were noted and the patients were tested for MPO-ANCA, antinuclear antibodies, blood urea nitrogen, creatinine and urine analysis. Twentysix patients (43.3%) reacted positively for MPO-ANCA, 23 were on PTU therapy (0.42 to 6.00, median 3.00 years) and three had discontinued PTU. There were 34 (56.7%) ANCA-negative patients and 27 patients on PTU therapy (0.25 to 5.17, median 1.00 years, p = 0.012). Vasculitis presented in 16 patients (26.7%), all of whom were receiving PTU at the time of the study. The percentage of vasculitis among MPO-ANCA positive patients was 27.6% more than in the negative group, p = 0.017. PTU was discontinued in patients with vasculitis and positive for MPO-ANCA. Our findings show a high prevalence of MPO-ANCA positivity and a significantly higher percentage of vasculitis among these patients, suggesting that patients taking PTU should be closely observed for the appearance of MPO-ANCA and signs of vasculitis, especially patients GD who have been treated for a long time. © Freund Publishing House Ltd., London.